Market Overview

UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on LifePoint Hospitals on Updated Estimates

Related LPNT
Benzinga's Top Upgrades, Downgrades For March 15, 2018
After A Q4 Miss, LifePoint Health Downgraded By Leerink On Free Cash Flow Concerns
By The Numbers: Healthcare Stocks With Big Cash Distributions (Seeking Alpha)

In a report published Wednesday, BMO Capital Markets reiterated its Market Perform rating on LifePoint Hospitals (NASDAQ: LPNT), and slightly raised its price target from $41.00 to $42.00.

BMO Capital Markets noted, “LifePoint posted a significant EPS beat for 4Q12. Operating revenues were aided by acquisitions but same-facility revenue per adjusted admission increased modestly as well during the quarter. An uptick to bad debt expense and meaningful use expenditures offset some of the top-line growth but EBITDA was still stronger than our estimate. Management issued 2013 guidance, showing a boost in revenues (driven largely by completed acquisitions) but contraction of EPS YOY. While the company's EBITDA forecast contained consensus for 2013, EPS was far below our previous estimate. Our estimates now include higher depreciation expenses paired with continued IT investments and some additional bad debt in 2013. We believe that 2014 earnings potential has pushed hospital valuations beyond fundamental support. We do not see enough potential upside to shares to get constructive here.”

LifePoint Hospitals closed on Tuesday at $44.86.

Latest Ratings for LPNT

Mar 2018Raymond JamesUpgradesMarket PerformOutperform
Mar 2018Leerink SwannDowngradesOutperformMarket Perform
Feb 2018Credit SuisseMaintainsNeutralNeutral

View More Analyst Ratings for LPNT
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings


Related Articles (LPNT)

View Comments and Join the Discussion!